Reuters

01 Jun 2026, 22:38 UTC · 2h ago

Abivax's inflammatory bowel drug meets main goal of late stage trial

Read original · https://www.reuters.com/business/healthcare-pharmaceuticals/abivaxs-inflammatory-bowel-drug-meets-main-goal-late-stage-trial-2026-06-01/

Search tags

Story key points

1 claims · impact-rated

What matters in this story

1
Abivax's experimental drug for ulcerative colitis met the primary endpoint of its late-stage clinical trial. — Successful late-stage trials are the most critical catalysts for biotech valuations as they pave the way for regulatory approval and commercialization.
+0.80

Ticker attribution

Model heads

Sentiment in this article

ABVX+1.00
The company's experimental drug met the main goal of a late-stage trial.

Relationships in this article

No ticker relationship head found.

Early access

You’re reading about it. Someone else is already positioned.

News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.

ABVX

Browse live screenings

Impact vectors

4 dimensions · 9 clusters

6 related stories

GlobeNewsWire
19h ago
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
- biotech
- clinical trials
- drug development
Read

Abivax's inflammatory bowel drug meets main goal of late stage trial… · News Impact Screener

Abivax's inflammatory bowel drug meets main goal of late stage trial

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

Abivax's inflammatory bowel drug meets main goal of late stage trial

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis Transcript

Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript

Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS)

Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares

Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases

Abivax's inflammatory bowel drug meets main goal of late stage trial

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Next reads from the same story arc

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

Abivax's inflammatory bowel drug meets main goal of late stage trial

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Next reads from the same story arc

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis Transcript

Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript

Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS)

Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares

Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases